Equity Insider 股权内参News Commentary 新闻评论Issued on behalf of GT Biopharma, Inc. (NASDAQ: 代表GT Biopharma公司（纳斯达克：GTBP GTBP) ）SAN FRANCISCO 旧金山, ，June 2, 2026 2026年6月2日/PRNewswire/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ: /PRNewswire/ -- 大多数处于临床阶段的肿瘤公司，若有三种药物正在人体试验中为患者给药，其估值通常高达数亿美元甚至更高。GT Biopharma公司（纳斯达克股票代码：GTBP 全球贸易与商业平台) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.. ）最近将其第三款药物推进临床试验——而整个公司的估值有时仅为其一小部分。该公司实验室研发进展与市场估值之间的落差正是问题的核心所在，而5月中旬达成的一项里程碑事件让这一落差变得尤为突出。On 开启 / 在……上May 14, 2026 2026年5月14日, GT Biopharma announced that the first patient had been dosed in a Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors. It is the third drug from the company's TriKE® platform to reach the clinic — and its first real push beyond blood cancers into the much larger solid-tumor opportunity.. GT生物制药公司宣布，GTB-5550的I期临床试验已完成首例患者给药，该药是一款靶向B7-H3、用于治疗实体瘤的自然杀伤（NK）细胞衔接器。这是该公司TriKE®平台第三款进入临床阶段的药物，也是其首次真正突破血液肿瘤领域，进军规模更为庞大的实体瘤市场机遇。See the full GT Biopharma pipeline and platform breakdown — 查看GT Biopharma完整的研发管线及平台详情——view the Equity Insider briefing here. 在此查看《Equity Insider》简报。Three drugs in the clinic from one platform 源自同一平台的三款临床阶段药物The May 14 dosing matters for a simple reason: it takes GT Biopharma from a company with a promising platform to one running two separate human trials at once. The first patient in the GTB-5550 Phase 1 dose-escalation basket trial joins ongoing work on GTB-3650, the company's second TriKE candidate, which has been enrolling patients with relapsed or refractory CD33-expressing blood cancers, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, in a design that steps through cohorts of two patients each. 5月14日的给药之所以重要，原因很简单：它使GT Biopharma从一家仅拥有前景广阔平台的药企，转变为一家同时开展两项独立人体临床试验的公司。GTB-5550 I期剂量递增篮子试验的首例患者已入组，与公司第二款TriKE候选药物GTB-3650的在研工作同步推进。GTB-3650试验目前正招募复发或难治性表达CD33的血液肿瘤患者，包括难治性急性髓系白血病和高危骨髓增生异常综合征，该试验采用每队列两名患者的设计逐步推进。For a company of GT Biopharma's size, having two candidates dosing simultaneously is unusual.. 对于GT Biopharma这样规模的公司而言，两款候选药物同时进行给药并不常见。GTB-5550 is also a milestone for the platform itself. It is the first of the company's TriKE molecules built as a dual-nanobody construct and the first designed for more patient-friendly subcutaneous dosing. The Phase 1 trial is structured as a basket study: a dose-escalation phase testing up to seven dose levels to find the maximum tolerated dose, followed by an expansion phase across multiple solid-tumor cohorts. GTB-5550对该平台本身而言也是一个里程碑。它是公司首款采用双纳米抗体结构构建的TriKE分子，也是首款设计为对患者更友好的皮下给药方式的分子。该1期临床试验采用篮式试验设计：首先开展剂量递增阶段，测试最多七个剂量水平以确定最大耐受剂量，随后在多个实体瘤队列中开展扩展阶段研究。Management has said the dose-escalation phase will prioritize prostate cancer, where the target antigen is especially relevant. CEO Michael Breen has framed bringing a third NK cell engager into the clinic as a defining moment for the company, and said updates are expected in the second half of 2026 as enrollment progresses.. 管理层表示，剂量递增阶段将优先针对前列腺癌，该靶点抗原在此类癌症中尤为相关。首席执行官迈克尔·布林（Michael Breen）将第三款NK细胞衔接器推进临床试验视为公司发展的里程碑时刻，并表示随着患者入组工作的推进，相关进展更新预计将于2026年下半年发布。What a TriKE actually does TriKE 的实际作用The science behind the valuation gap is worth understanding, because it is the same approach the largest names in cancer immunotherapy are spending heavily to pursue. Natural killer cells are part of the body's innate immune system — fast-acting cells that can destroy diseased cells without the priming that conventional T cells require. 了解这一估值差距背后的科学原理颇具价值，因为这正是癌症免疫治疗领域的巨头们正斥巨资投入研发的同一路径。自然杀伤细胞是人体先天免疫系统的一部分——这类细胞起效迅速，无需像传统T细胞那样经过致敏启动过程，即可直接摧毁病变细胞。The challenge has always been pointing them at a tumor reliably. GT Biopharma's TriKE, or tri-specific killer engager, is a single engineered molecule with three jobs: one arm grabs the CD16 activating receptor on an NK cell, a middle segment built from the cytokine IL-15 keeps those NK cells alive and multiplying, and a third arm latches onto a specific marker on the tumor. 一直以来的挑战在于如何可靠地将其靶向肿瘤。GT Biopharma公司的TriKE（三特异性杀伤细胞衔接器）是一种具备三种功能的单一工程化分子：其一臂结合NK细胞上的CD16激活受体，由细胞因子IL-15构成的中间段负责维持这些NK细胞的存活与增殖，第三臂则锁定肿瘤上的特定标记物。The result is meant to be an off-the-shelf molecule that recruits a patient's own NK cells and drives them onto cancer.. 该成果旨在成为一种即用型分子，能够招募患者自身的NK细胞并引导其攻击癌细胞。For GTB-5550, that tumor-targeting arm is aimed at B7-H3, a protein that shows up on a broad range of solid tumors and is expressed in the large majority of metastatic castration-resistant prostate cancers — which is why prostate cancer leads the dose-escalation phase. The platform was licensed from the University of Minnesota, which retains a royalty interest should any TriKE product reach commercial sales. 对于GTB-5550，其肿瘤靶向臂针对的是B7-H3蛋白。该蛋白广泛表达于多种实体瘤中，且绝大多数转移性去势抵抗性前列腺癌均表达该蛋白——这也是前列腺癌适应症率先开展剂量递增阶段试验的原因。该平台技术获授权自明尼苏达大学，若任何TriKE产品实现商业化销售，该校将保留收取特许权使用费的权益。That academic pedigree, and the fact that three distinct TriKE candidates are now in human testing, is the core of the bull case: a validated-looking platform attached to a very small market capitalization.. 这种学术背景，加上三种不同的TriKE候选药物目前已进入人体试验阶段这一事实，构成了看多逻辑的核心：一个看似已获验证的平台，却对应着极低的市值。Want the full TriKE platform science and trial design? 想了解完整的TriKE平台科学原理与试验设计吗？Explore the GT Biopharma breakdown here. 在此查看 GT Biopharma 的详细分析。The other side of a micro-cap story 微盘股故事的另一面The reason the market has assigned GT Biopharma such a small valuation is not a mystery, and an honest read has to weigh it. This is a clinical-stage company with no approved products and no product revenue, and its reported cash position — around $9 million as of early 2026 — was described as sufficient to fund operations only into the fourth quarter of 2026. 市场给予GT Biopharma如此低估值的原因并不神秘，任何客观的分析都必须对此加以考量。这是一家处于临床阶段的公司，既无获批产品，也无产品收入；其公布的现金状况——截至2026年初约为900万美元——据称仅能支撑公司运营至2026年第四季度。That is a short runway for a company running three trials, and it implies the need for additional financing, which for a micro-cap typically means dilution. The company has filed to register shares for resale, and a sell-side analyst at Roth Capital cut the price target earlier in the year even while maintaining a constructive stance.. 对于一家同时推进三项试验的公司而言，其现金跑道已显不足，这意味着需要额外融资；而对于微型市值公司来说，这通常意味着股权稀释。该公司已提交股票转售注册申请，且罗斯资本的一名卖方分析师在今年早些时候下调了目标价，尽管仍维持建设性看法。None of that is hidden, and none of it changes the underlying science — but it is the context against which the platform's promise has to be measured. Early-stage oncology trials carry high failure rates, dose-escalation results can disappoint, and a company this thinly capitalized has little margin for setbacks. 这一切均未被隐瞒，也未改变其底层科学逻辑——但正是这些构成了评估该平台前景时必须考量的背景。早期肿瘤临床试验失败率极高，剂量递增试验的结果可能不尽如人意，而这样一家资金单薄的公司几乎没有任何承受挫折的余地。The asymmetry that attracts speculative investors — a real platform at a tiny valuation — exists precisely because the risks are real. Investors should size any interest against the financing and clinical risk that comes with it.. 吸引投机性投资者的这种不对称性——即以极低估值获得真实平台——之所以存在，正是因为其风险是真实存在的。投资者应结合随之而来的融资风险与临床风险来合理确定投资规模。Four NK and cell-therapy names investors watch in the same space 投资者在同一赛道关注的四家NK细胞与细胞疗法公司。GT Biopharma is one of a cluster of companies trying to turn natural killer cells and related immune cells into cancer drugs. The peer group below shows how differently the market values programs at various stages — and how much capital is chasing the same fundamental idea. GT Biopharma 是众多致力于将自然杀伤细胞及相关免疫细胞开发为抗癌药物的公司之一。下方的同行企业对比显示，市场对处于不同研发阶段的项目估值存在显著差异——同时也反映出有多少资本正在竞相追逐这一相同的核心理念。Innate Pharma S.A. (NASDAQ: 英纳特制药股份有限公司（纳斯达克：IPHA 国际公共卫生协会) ）is the closest mechanistic comparison. Its proprietary ANKET® platform builds multi-specific NK cell engagers — the same broad class of molecule as GT Biopharma's TriKE. Its CD123-targeted engager advanced into Phase 2 dose-expansion testing in blood cancers and carries FDA Fast Track designation; originally developed under a long-running Sanofi collaboration, the program's rights returned to Innate in 2025 as the company reprioritized its pipeline. 是机制上最为接近的对照。其专有的ANKET®平台用于构建多特异性NK细胞衔接器，与GT Biopharma公司的TriKE属于同一大类分子。其靶向CD123的衔接器已进入血液肿瘤的2期剂量扩展试验阶段，并获FDA快速通道资格；该项目最初系在与赛诺菲的长期合作下开发，随着公司重新调整研发管线优先级，相关权益已于2025年回归Innate公司。Innate shows both the promise and the turbulence of the NK-engager field — a platform that drew major-pharma partnership, and the strategic resets that can follow.. Innate展现了NK细胞接合器领域的前景与动荡——这一平台曾吸引大型药企合作，却也随之引发了战略调整。MiNK Therapeutics, Inc. (NASDAQ: MiNK Therapeutics公司（纳斯达克：INKT INKT) ）takes a related but distinct approach, developing off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies. Its lead candidate, agenT-797, recently moved into a randomized Phase 2 trial in severe acute lung injury, with preliminary data expected in the second half of 2026, and its cancer work has shown durable activity signals in solid tumors. 采取了一种相关但不同的策略，致力于开发现货型异体不变自然杀伤T（iNKT）细胞疗法。其领先候选药物agenT-797近期已进入针对严重急性肺损伤的随机2期临床试验，初步数据预计将于2026年下半年公布；此外，其在肿瘤领域的研究已在实体瘤中展现出持久的活性信号。MiNK reported roughly $9.5 million in cash with a net loss of about $2.7 million for the first quarter of 2026 — a balance-sheet profile strikingly similar to GT Biopharma's, underscoring how tight capital is across the small end of this field.. MiNK报告显示，2026年第一季度其现金储备约为950万美元，净亏损约270万美元——这一资产负债表状况与GT Biopharma极为相似，凸显了该领域小型企业资金普遍紧张的现状。Century Therapeutics, Inc. (NASDAQ: 世纪疗法公司（纳斯达克：IPSC 国际实用射击联盟) ）represents the better-capitalized end of the cell-therapy spectrum. The company develops allogeneic, iPSC-derived NK and engineered immune-cell therapies — including a CAR-iNK candidate — using a proprietary gene-editing approach designed to help the cells evade host rejection. With cash and investments reported around $117 million at the end of 2025, bolstered by an oversubscribed $135 million private placement completed in early 2026 that extended its runway into 2029, Century shows how much further a similar scientific thesis can be pushed when the balance sheet allows it.. 代表了细胞疗法领域中资本更为雄厚的一端。该公司利用专有的基因编辑技术开发异体iPSC来源的NK细胞及工程化免疫细胞疗法（含一款CAR-iNK候选药物），该技术旨在帮助细胞逃避免疫排斥。截至2025年底，该公司账面现金及投资约1.17亿美元；凭借2026年初超额认购完成的1.35亿美元私募融资，其资金跑道已延长至2029年。Century公司表明，在资金实力的支撑下，类似的科学研发理念能够被推进到何种深度。NKGen Biotech, Inc. (OTC: NKGN) NKGen生物科技公司（OTC：NKGN）rounds out the group on the autologous NK-cell side. Its lead candidate, troculeucel (also known as SNK01), is an expanded NK cell therapy the company is developing across both neurodegenerative disease and cancer; it reported combined Phase 1 data in Alzheimer's disease in early 2026 and holds an expanded-access authorization. 补全了自体NK细胞领域的布局。其核心候选药物troculeucel（又称SNK01）是一种扩增型NK细胞疗法，公司正同步在神经退行性疾病和癌症领域推进研发；该药物已于2026年初公布了针对阿尔茨海默病的汇总1期临床数据，并已获得扩大使用授权。NKGen illustrates how broadly the NK-cell approach is being applied — well beyond oncology — and, as an over-the-counter-listed micro-cap, the financing challenges that come with the territory.. NKGen展示了NK细胞疗法的应用范围之广——已远超肿瘤学领域；同时，作为一家在OTC市场上市的微型市值公司，它也面临着随之而来的融资挑战。Across all four, the shared thread is the one driving attention to GT Biopharma: NK and related immune-cell therapies are a field large pharmaceutical companies are investing in heavily, and the market has assigned the public players valuations ranging from the tens of millions into the billions depending on stage, data, and balance sheet. 在这四者中，共同的主线正是引发市场关注GT生物制药（GT Biopharma）的核心逻辑：NK细胞及相关免疫细胞疗法是大型制药企业正大力投资的领域，而市场根据各上市公司的研发阶段、数据表现及资产负债状况，赋予它们的估值从数千万美元到数十亿美元不等。GT Biopharma sits at the small, early, high-risk end — with three clinical programs and a platform that, on paper, belongs in the same conversation.. GT Biopharma 处于规模较小、处于早期且高风险的一端——公司拥有三个临床项目，以及一个在纸面上完全有资格被纳入同一讨论范畴的技术平台。What to watch from here 接下来值得关注什么For GT Biopharma specifically, the near-term catalysts are clear. The most important is data: the company has guided to updates in the second half of 2026 from both the new GTB-5550 solid-tumor trial as enrollment moves through dose-escalation cohorts, and the ongoing GTB-3650 blood-cancer trial. Alongside the clinical readouts, investors will watch the financing question closely — how, and on what terms, a company with a runway into late 2026 funds three trials — since the answer bears directly on dilution and the path forward.. 具体到GT Biopharma，近期的催化剂十分明确。最重要的是数据：公司指引称，随着全新GTB-5550实体瘤试验的受试者入组逐步推进至剂量递增队列，以及GTB-3650血液肿瘤试验的持续开展，预计将在2026年下半年发布相关数据更新。除临床数据读出外，投资者还将密切关注融资问题——一家资金跑道仅能维持至2026年末的公司将如何、以何种条款为三项临床试验筹集资金——因为该问题的答案将直接关系到股权稀释程度与公司的未来发展路径。None of this changes the fundamental reality that GT Biopharma is a development-stage, thinly capitalized company whose value rests entirely on early clinical data and its ability to keep funding the work. But the combination of three TriKE candidates now in human trials, a platform licensed from a leading cancer-research university, and a valuation that sits far below its NK-cell peers is the kind of setup that draws speculative attention. 这一切都不会改变一个基本事实：GT Biopharma 是一家处于研发阶段、资本薄弱的公司，其价值完全取决于早期临床数据及其持续为研发工作提供资金的能力。然而，三款 TriKE 候选药物目前已进入人体试验阶段、技术平台获顶尖癌症研究大学授权，以及其估值远低于 NK 细胞领域的同类公司，这种组合恰恰构成了吸引投机性关注的典型局面。Whether the gap closes — and in which direction — will be decided by the data and the balance sheet over the months ahead.. 缺口是否会弥合——以及朝哪个方向——将由未来几个月的数据和资产负债表来决定。Stay ahead of the next GT Biopharma milestone — 抢先掌握GT Biopharma的下一个里程碑 ——get updates and the full story here. 在此获取最新动态及完整详情。Contact: 联系方式：USA News Group 美国新闻集团[emailprotected] [email protected]604-265-2873 604-265-2873About GT Biopharma 关于GT生物制药GT Biopharma, Inc. (NASDAQ: GT生物制药公司（NASDAQ：GTBP GTBP) is a clinical-stage immuno-oncology company developing therapeutics based on its proprietary TriKE® (tri-specific killer engager) natural killer cell engager platform, licensed from the University of Minnesota. Its clinical candidates include GTB-3650, in a Phase 1 trial for CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted NK cell engager in a Phase 1 trial for solid tumors. ）是一家处于临床阶段的免疫肿瘤公司，基于其获明尼苏达大学授权的专有TriKE®（三特异性杀伤细胞接合器）自然杀伤细胞接合器平台开发治疗药物。其临床候选药物包括GTB-3650（正在进行针对表达CD33的血液系统恶性肿瘤的I期临床试验），以及GTB-5550（一种靶向B7-H3的NK细胞接合器，正在进行针对实体瘤的I期临床试验）。Michael Breen serves as Executive Chairman and Chief Executive Officer.. 迈克尔·布林担任执行董事长兼首席执行官。Disclaimer / Disclosure 免责声明 / 披露Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. 本出版物中的任何内容均不应被视为个性化财务建议。我们未依据证券法取得针对您特定财务状况提供建议的资质。我方员工与您的任何沟通均不得视为个性化财务建议。在作出任何投资决策前，请咨询持牌财务顾问。This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. 本内容仅为数字媒体发布，既不构成购买或出售任何证券的要约，也不构成相关推荐。我们未持有任何投资牌照，因此既无许可也无资格提供投资建议。本报告或电子邮件中的内容并非针对任何个人的具体情况而提供。While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. 尽管所有信息均被认为可靠，但我们不保证其准确性。个人应假定本通讯中所含的全部信息均不可信，除非其已通过独立研究自行核实。此外，由于事件与情况往往不会按预期发生，任何预测与实际结果之间很可能存在差异。Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.. 在作出任何投资决策前，请务必咨询持牌投资专业人士。请格外谨慎，证券投资具有高风险；您可能会损失部分或全部投资。USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). This article is being distributed by USA News Group on behalf of MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Direct Marketing Group ('CDMG'). There may be 3rd parties who may have shares of GT Biopharma, Inc. USA News Group 是 Market IQ Media Group, Inc.（简称“MIQ”）的全资子公司。本文由 USA News Group 代表 MIQ 发布。MIQ 已从 Creative Direct Marketing Group（简称“CDMG”）处收取了 GT Biopharma, Inc. 广告及数字媒体的相关费用。可能有第三方持有 GT Biopharma, Inc. 的股份。and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. 并可能抛售其股份，从而可能对股价产生负面影响。该报酬构成利益冲突，会影响我们在就所介绍公司进行沟通时保持客观的能力。鉴于此利益冲突，强烈建议个人不要将本文或本邮件作为任何投资决策的依据。The owner/operator of MIQ currently owns shares of GT Biopharma, Inc. that were purchased in the open market and reserves the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of GT Biopharma, Inc. MIQ的所有者/运营者目前持有在公开市场购入的GT Biopharma, Inc.股份，保留买卖该等股份的权利，并将自即日起持续在任何时间买卖GT Biopharma, Inc.股份，且不再另行通知。此外，我们还将就持续开展的旨在提升该公司知名度的数字媒体推广工作获得进一步报酬；此后不再另行通知，但谨以本免责声明作为正式通知：MIQ发布的所有材料均已代表GT Biopharma, Inc.审阅并获批准。by CDMG; this is a digital media distribution.. 由CDMG提供；此为数字媒体发行版。While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. 尽管所有信息均被视为可靠，但我们不保证其准确性。个人应假定本文所载信息均不可信，除非经其自身独立研究核实。此外，由于实际情况往往与预期不符，任何预测与实际结果之间很可能存在差异。Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.. 在做出任何投资决策前，请务必咨询持牌投资专业人士。请格外谨慎，投资证券具有极高风险；您可能会损失部分或全部投资本金。Certain statements in this article constitute 'forward-looking information,' including statements regarding clinical trial initiation, enrollment, and timing; anticipated data updates; the TriKE platform and its candidates; cash runway and financing; and the markets for NK-cell and immuno-oncology therapies. 本文中的某些陈述构成“前瞻性信息”，包括关于临床试验启动、受试者入组及时间安排；预期数据更新；TriKE平台及其候选药物；现金跑道与融资安排；以及NK细胞疗法和肿瘤免疫疗法市场的陈述。Such statements are subject to risks and uncertainties — including clinical and regulatory risk, early-stage trial failure rates, financing and dilution risk, going-concern and liquidity considerations, competition, and other factors — that could cause actual results to differ materially. Readers are advised not to place undue reliance on forward-looking information. 此类陈述受风险和不确定因素影响——包括临床与监管风险、早期试验失败率、融资与稀释风险、持续经营与流动性考量、竞争及其他因素——可能导致实际结果发生重大差异。建议读者勿对前瞻性信息过度依赖。Comparable companies referenced herein are independent third parties included for industry context only; their inclusion is not a comparison of investment merit, and MIQ has no relationship with them.. 此处提及的可比公司均为独立第三方，仅用于提供行业背景参考；将其列入并非用于比较投资价值，且MIQ与这些公司不存在任何关联。Logo - 标志 -https://mma.prnewswire.com/media/2838876/5997491/USA_News_Group_Logo.jpg https://mma.prnewswire.com/media/2838876/5997491/USA_News_Group_Logo.jpgSOURCE USA News Group 来源：美国新闻集团21 二十一% 百分号more press release views with 通过……获得更多新闻稿浏览量Request a Demo 申请演示
